CliffBio
small molecule

ATORVALIQ

ATORVASTATIN CALCIUM

Loss of exclusivityJune 2037latest FDA-listed patent expiry
CompanyCMP DEVELOPMENT LLC

Drug detail

Brand nameATORVALIQ
Active ingredientATORVASTATIN CALCIUM
Strength20MG/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2023
Marketing statusRX

Listed patents

PatentExpiresType
11654106June 2037product
11925704June 2037product
12370136June 2037product
12599553June 2037product
12168069June 2037product
11369567June 2037product

More from CMP DEVELOPMENT LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ATORVALIQ patent cliff — loss of exclusivity June 2037 | CliffBio